MA30073B1 - Derives de piperidine 3,5-substitues en tant qu'inhibiteurs de renine - Google Patents

Derives de piperidine 3,5-substitues en tant qu'inhibiteurs de renine

Info

Publication number
MA30073B1
MA30073B1 MA31057A MA31057A MA30073B1 MA 30073 B1 MA30073 B1 MA 30073B1 MA 31057 A MA31057 A MA 31057A MA 31057 A MA31057 A MA 31057A MA 30073 B1 MA30073 B1 MA 30073B1
Authority
MA
Morocco
Prior art keywords
substituted piperidine
treatment
renin
compound
disease
Prior art date
Application number
MA31057A
Other languages
English (en)
Inventor
Takeru Ehara
Philipp Grosche
Osamu Irie
Yuki Iwaki
Takanori Kanazawa
Shimpei Kawakami
Kazuhide Konishi
Muneto Mogi
Masaki Suzuki
Fumiaki Yokokawa
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37875514&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30073(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0604223A external-priority patent/GB0604223D0/en
Priority claimed from GB0611390A external-priority patent/GB0611390D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30073B1 publication Critical patent/MA30073B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Composés organiques L'invention se rapporte à des composés de pipéridine 3,5-substitués, ces composés sont employés pour le traitement diagnostique et thérapeutique d'un animal à sang chaud, tout particulièrement pour le traitement d'une maladie (= trouble) qui dépend de l'activité de la rénine ; à l'utilisation d'un composé de cette classe pour la préparation d'une préparation pharmaceutique destinée au traitement d'une maladie qui dépend de l'activité de la rénine ; à l'utilisation d'un composé de cette classe dans le traitement d'une maladie qui dépend de l'activité de la rénine ; à des préparations pharmaceutiques comprenant un composé de pipéridine 3,5-substitué, et/ou à une méthode de traitement consistant à administrer de pipéridine 3,5-substitué, à une méthode de fabrication d'un composé de pipéridine 3,5-substitué, et à de nouveaux intermédiaires et aux étapes partielles de leur synthèse. Les composés préférés (qui peuvent également être présents en tant que sels) possèdent la formule I¿ dans laquelle, R1, R2, T, R3 et R4 sont tels que définis dans la description.
MA31057A 2005-12-30 2008-06-19 Derives de piperidine 3,5-substitues en tant qu'inhibiteurs de renine MA30073B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05028771 2005-12-30
GB0604223A GB0604223D0 (en) 2006-03-02 2006-03-02 Organic compounds
GB0611390A GB0611390D0 (en) 2006-06-08 2006-06-08 Organic compounds

Publications (1)

Publication Number Publication Date
MA30073B1 true MA30073B1 (fr) 2008-12-01

Family

ID=37875514

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31057A MA30073B1 (fr) 2005-12-30 2008-06-19 Derives de piperidine 3,5-substitues en tant qu'inhibiteurs de renine

Country Status (20)

Country Link
US (1) US8129411B2 (fr)
EP (2) EP1968940B1 (fr)
JP (1) JP5306821B2 (fr)
KR (1) KR20080086921A (fr)
AR (1) AR058885A1 (fr)
AU (1) AU2006332124B2 (fr)
BR (1) BRPI0620736A2 (fr)
CA (1) CA2633624C (fr)
CR (1) CR10091A (fr)
EC (1) ECSP088587A (fr)
ES (2) ES2476422T3 (fr)
IL (1) IL192024A0 (fr)
MA (1) MA30073B1 (fr)
NO (1) NO20083315L (fr)
NZ (1) NZ569135A (fr)
PE (2) PE20110117A1 (fr)
PL (1) PL2420491T3 (fr)
PT (1) PT2420491E (fr)
TW (1) TW200738698A (fr)
WO (1) WO2007077005A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0514203D0 (en) * 2005-07-11 2005-08-17 Novartis Ag Organic compounds
BRPI0620736A2 (pt) 2005-12-30 2011-12-20 Novartis Ag compostos orgánicos
ES2729424T3 (es) 2006-09-20 2019-11-04 Aerie Pharmaceuticals Inc Inhibidores de Rho cinasa
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8129538B1 (en) 2007-03-28 2012-03-06 Takeda Pharmaceutical Company Limited Renin inhibitors
SG182223A1 (en) 2007-06-25 2012-07-30 Novartis Ag N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors
WO2009051112A1 (fr) 2007-10-15 2009-04-23 Takeda Pharmaceutical Company Limited Composés amides et leur utilisation
JP5484069B2 (ja) 2007-12-19 2014-05-07 大日本住友製薬株式会社 二環性へテロ環誘導体
KR101403311B1 (ko) 2008-05-05 2014-06-05 액테리온 파마슈티칼 리미티드 레닌 억제제로서의 3,4-치환된 피페리딘 유도체
NZ600238A (en) 2008-06-19 2014-04-30 Takeda Pharmaceutical Heterocyclic compound and use thereof
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US20120115907A1 (en) * 2009-04-24 2012-05-10 Cadila Healthcare Limited Novel compounds as inhibitors of renin
EP3828172A1 (fr) 2009-05-01 2021-06-02 Aerie Pharmaceuticals, Inc. Inhibiteurs à double mecanisme pour le traitement d'une maladie
KR20120109292A (ko) 2009-06-24 2012-10-08 다이닛본 스미토모 세이야꾸 가부시끼가이샤 Ｎ-치환-시클릭 아미노 유도체
KR20140092696A (ko) * 2013-01-16 2014-07-24 주식회사유한양행 신규의 페닐에티닐 벤즈아마이드 글루코키나제 활성화제 및 그의 제조방법
ES2852377T3 (es) 2013-03-15 2021-09-13 Aerie Pharmaceuticals Inc Sales dimesilato de 4-(3-amino-1-(isoquinolin-6-ilamino)-1-oxopropan-2-il)bencilo, sus combinaciones con prostaglandinas y el uso de las mismas en el tratamiento de trastornos oculares
EP3130581A4 (fr) 2014-04-10 2017-11-22 Takeda Pharmaceutical Company Limited Procédé de production d'un composé hétérocyclique
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
KR102579582B1 (ko) * 2015-11-17 2023-09-15 에어리 파마슈티컬즈, 인코포레이티드 키나아제 억제제 및 이의 중간체의 제조 방법
KR102568079B1 (ko) 2016-08-31 2023-08-17 에어리 파마슈티컬즈, 인코포레이티드 안과용 조성물
AU2018243687C1 (en) 2017-03-31 2020-12-24 Alcon Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
CA3112391A1 (fr) 2018-09-14 2020-03-19 Aerie Pharmaceuticals, Inc. Composes d'amide aryl cyclopropyl-amino-isoquinolinyl
CN117986146A (zh) * 2023-12-22 2024-05-07 河南优凯制药有限公司 一种枸橼酸喷托维林杂质的制备方法及其检测方法
CN119059970B (zh) * 2024-08-30 2026-03-24 上海信诺维生物医药有限公司 一种btk抑制剂药物中间体的制备方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224941B (fr) 1989-11-08 1994-06-11 Yamanouchi Pharma Co Ltd
US5463074A (en) 1991-12-18 1995-10-31 Schering Corporation Imidazolyl or imidazoylalkyl substituted with a four or five membered nitrogen containing heterocyclic ring
IL111176A0 (en) 1993-10-07 1994-12-29 Du Pont Merck Pharma Dipeptide boronic acid inhibitors of trypsin-like enzymes and pharmaceutical compositions containing them
TR199800409T1 (xx) 1995-09-07 1998-05-21 F.Hoffmann-La Roche Ag Kalp ve b�brek yetersizli�inin tedavii�in yeni 4-(oksialkoksifenil)-3-oksi-piperidinler
JP2000500502A (ja) * 1995-11-22 2000-01-18 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
EP1009405A4 (fr) 1997-08-28 2001-05-09 Merck & Co Inc Modulateurs de pyrrolidine et de piperidine de l'activite du recepteur de chemokine
CA2333554A1 (fr) 1998-06-17 1999-12-23 Chu-Baio Xue Acides hydroxamiques cycliques utilises en tant qu'inhibiteurs de metalloproteases
US6274735B1 (en) 1998-08-10 2001-08-14 Hoffmann-La Roche Inc. Process and intermediates for preparation of substituted piperidines
WO2000026211A1 (fr) 1998-10-30 2000-05-11 Merck & Co., Inc. Inhibiteurs de la thrombine
AU3389300A (en) 1999-03-02 2000-09-21 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
AU3386700A (en) 1999-03-02 2000-09-21 Merck & Co., Inc. 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
US6362201B1 (en) 1999-03-02 2002-03-26 Merck & Co., Inc. 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity
WO2000063173A1 (fr) 1999-04-14 2000-10-26 F. Hoffmann-La Roche Ag Procede de preparation de piperidines substituees
US6197959B1 (en) 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
US6376672B1 (en) 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
IL151552A0 (en) 2000-03-17 2003-04-10 Bristol Myers Squibb Pharma Co Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
WO2001074741A2 (fr) * 2000-04-04 2001-10-11 Brandeis University Désymétrisation catalytique asymétrique de composés méso
FR2811673B1 (fr) 2000-07-17 2002-09-13 Rhodia Chimie Sa Utilisation de composes insatures comprenant un heterocycle comme stabilisants de polymeres halogenes
CA2425288A1 (fr) 2000-10-11 2002-05-02 Sander G. Mills Modulateurs a base de pyrrolidine d'activite de recepteur de chimiokines ccr5
US20060079533A1 (en) 2001-03-23 2006-04-13 Nieman James A Methods of treating alzheimer's disease
EP1389194A2 (fr) 2001-04-27 2004-02-18 Vertex Pharmaceuticals Incorporated Inhibiteurs de bace
US6740649B2 (en) 2001-09-17 2004-05-25 Bristol-Myers Squibb Company Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF- α converting enzyme (TACE)
WO2003031443A1 (fr) 2001-10-04 2003-04-17 Morphochem Aktiengesellschaft für kombinatorische Chemie Antibiotiques a action duale renfermant une oxazolidinone et une quinolone ou une fraction de naphthyridinone
CA2483241C (fr) 2002-04-29 2011-05-31 Actelion Pharmaceuticals Ltd Nouveaux derives de diazabicyclononene
JP4271148B2 (ja) 2002-05-20 2009-06-03 ブリストル−マイヤーズ スクイブ カンパニー 置換シクロアルキルｐ１’ｃ型肝炎ウイルスインヒビター
AU2003259131A1 (en) 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US20040204455A1 (en) 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
US20040214832A1 (en) 2003-04-10 2004-10-28 Cuiman Cai Piperazine derivative renin inhibitors
CN1780836A (zh) 2003-04-28 2006-05-31 埃科特莱茵药品有限公司 作为血管紧张肽原酶抑制剂的新型二氮杂双环壬烯和四氢吡啶衍生物
JP2007523845A (ja) 2003-04-29 2007-08-23 アクテリオン　ファマシューティカルズ　リミテッド 新規３，４−ジ置換１，２，３，６−テトラヒドロピリジン誘導体
KR20060006069A (ko) 2003-04-30 2006-01-18 액테리온 파마슈티칼 리미티드 아자비사이클로노넨 유도체
JP2006524657A (ja) 2003-04-30 2006-11-02 アクテリオン　ファマシューティカルズ　リミテッド 新規トロパン誘導体
KR20060008937A (ko) 2003-04-30 2006-01-27 액테리온 파마슈티칼 리미티드 레닌 억제제로서 3-위치에 헤테로원자를 갖는9-아자비사이클로[3.3.1]논-6-엔 유도체
EP1622564A2 (fr) 2003-05-02 2006-02-08 Actelion Pharmaceuticals Ltd. Derives de diazabicyclononene
TW200900399A (en) 2003-10-01 2009-01-01 Speedel Experimenta Ag Organic compounds
CA2540543A1 (fr) 2003-10-09 2005-05-06 Actelion Pharmaceuticals Ltd Derives de tetrahydropyridine
CN1906163A (zh) 2003-11-26 2007-01-31 诺瓦提斯公司 作为肾素抑制剂的4－苯基哌啶衍生物
JP4884230B2 (ja) 2003-11-26 2012-02-29 ノバルティス アーゲー 有機化合物
BRPI0506491A (pt) 2004-01-23 2007-02-13 Speedel Experimenta Ag compostos orgánicos
EP1711456A2 (fr) 2004-01-23 2006-10-18 Speedel Experimenta AG Derives d' amino alcohol et leur utilisation comme inhibiteurs de la renine
ATE472524T1 (de) 2004-01-23 2010-07-15 Novartis Ag Diaminoalkohole und deren verwendung als renininhibitoren
TW200609215A (en) 2004-03-19 2006-03-16 Speedel Experimenta Ag Organic compounds
EP1724259A1 (fr) 2004-03-19 2006-11-22 Speedel Experimenta AG Dérivés 5-amino-4-hydroxy-8-(1h-indazol-5-yl)-octan amide substitués 2,7 et composés similaires comme inhibiteurs du rénin pour le traitement de hypertension
AR053406A1 (es) 2004-07-09 2007-05-09 Speedel Experimenta Ag Derivados de piperidina como inhibidores de renina. composiciones farmaceuticas
TW200631929A (en) 2004-12-10 2006-09-16 Speedel Experimenta Ag ω -phenyloctanamides
GB0428250D0 (en) 2004-12-23 2005-01-26 Novartis Ag Organic compounds
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
GB0500784D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0504850D0 (en) 2005-03-09 2005-04-13 Novartis Ag Organic compounds
US20080176947A1 (en) 2005-03-11 2008-07-24 Peter Herold Heterocyclic-Substituted Alkanamides Useful as Renin Inhibitors
GB0505969D0 (en) 2005-03-23 2005-04-27 Novartis Ag Organic compounds
BRPI0609534A2 (pt) 2005-03-31 2010-04-13 Speedel Experimenta Ag piperidinas 3,4,5-substituìdas
TW200722424A (en) 2005-03-31 2007-06-16 Speedel Experimenta Ag Substituted piperidines
GB0508992D0 (en) 2005-05-03 2005-06-08 Novartis Ag Organic compounds
GB0510810D0 (en) 2005-05-26 2005-06-29 Novartis Ag Organic compounds
GB0511063D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0514203D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
CA2622375A1 (fr) 2005-09-17 2007-03-22 Speedel Experimenta Ag Amides d'acide alcanoique substitues par des o-heterocycles satures
BRPI0617166A2 (pt) 2005-09-17 2011-07-12 Speedel Experimenta Ag derivados de 5-amino-4-hidróxi-7-(imidazo[1,2-a]piridin-6-ilmetil)-8-me til-nonamidia e compostos relacionados como inibidores de renina para o tratamento de hipertensão
PE20071079A1 (es) 2005-11-15 2007-12-16 Cytokinetics Inc Compuestos de piperidina como inhibidores de la proliferacion celular
BRPI0620736A2 (pt) 2005-12-30 2011-12-20 Novartis Ag compostos orgánicos
EP1816122A3 (fr) 2006-01-19 2007-09-19 Speedel Experimenta AG Pipéridines substituées 3,4,5 en tant que composants thérapeutiques
JP2009525304A (ja) 2006-01-30 2009-07-09 シュペーデル・エクスペリメンタ・アーゲー α，β−不飽和化合物からのアルコールの立体選択的製造方法
TW200815425A (en) 2006-06-08 2008-04-01 Speedel Experimenta Ag 2,5-disubstituted piperidines
GB0611697D0 (en) 2006-06-13 2006-07-26 Novartis Ag Organic compounds
GB0611696D0 (en) 2006-06-13 2006-07-26 Novartis Ag Organic compounds
EP1908471A1 (fr) 2006-10-04 2008-04-09 Speedel Experimenta AG Tétrahydropyridines comme inhibiteurs de la renine

Also Published As

Publication number Publication date
AU2006332124A1 (en) 2007-07-12
ECSP088587A (es) 2008-07-30
PT2420491E (pt) 2013-10-14
WO2007077005A1 (fr) 2007-07-12
EP2420491B1 (fr) 2013-07-03
IL192024A0 (en) 2008-12-29
EP1968940A1 (fr) 2008-09-17
TW200738698A (en) 2007-10-16
PL2420491T3 (pl) 2013-12-31
EP1968940B1 (fr) 2014-04-02
NO20083315L (no) 2008-09-19
ES2476422T3 (es) 2014-07-14
BRPI0620736A2 (pt) 2011-12-20
AU2006332124B2 (en) 2011-03-03
PE20110117A1 (es) 2011-03-07
CA2633624A1 (fr) 2007-07-12
ES2430139T3 (es) 2013-11-19
JP5306821B2 (ja) 2013-10-02
EP2420491A1 (fr) 2012-02-22
PE20071177A1 (es) 2008-01-18
JP2009522226A (ja) 2009-06-11
NZ569135A (en) 2011-08-26
US8129411B2 (en) 2012-03-06
KR20080086921A (ko) 2008-09-26
CA2633624C (fr) 2013-11-19
CR10091A (es) 2008-10-27
AR058885A1 (es) 2008-02-27
US20090192148A1 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
MA30073B1 (fr) Derives de piperidine 3,5-substitues en tant qu'inhibiteurs de renine
MA29379B1 (fr) Derives de pyrrolidine 3,4-substitues pour le traitement de l'hypertension
MA27937A1 (fr) Dérivés d'indazole 3, 5-disubstitués, compositions pharmaceutiques, et méthodes de médiation ou d'inhibition de la prolifération cellulaire
MA59968B1 (fr) Composés de cyclobutyle dihydroquinoléine sulfonamide
MA63501B1 (fr) Dérivés d'urée pouvant être utilisés pour traiter le cancer
TNSN05298A1 (fr) Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases
MA27347A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
MA30089B1 (fr) (arylsulfonyl)-pyrasolopiperidines
TNSN05250A1 (fr) Pyrimidinones substituees
TNSN04156A1 (fr) Pyridinones substituees servant de modulateurs de la map-kinase p38
TNSN05104A1 (fr) Derives de thiazole pour le traitement de troubles neurodegeneratifs
TNSN05037A1 (fr) Derives heterobiaryliques servant d'inhibiteurs de metalloproteinases de matrice
TNSN07476A1 (fr) Derives de n-(pyridine -2- yl) - sulfonamide
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA29807B1 (fr) Dérives de phenyl-[1,2,4]- oxadiazol-5-one avec un groupement phényle, leurs procédés de préparation et leur utilisation comme produits pharmaceutiques.
MA33502B1 (fr) Composés pyrazolopyrimidine inhibiteurs des jak et procédés
TNSN07349A1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
MA28064A1 (fr) Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases
MA27129A1 (fr) Les pyrrolopyrimidines en tant qu'inhibiteurs du kinase de proteine.
BRPI0519443A2 (pt) composto orgÂnicos
MA29723B1 (fr) Composes
MA29566B1 (fr) Composes chimiques
BR0210392A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
MX2007011009A (es) Compuestos de piperidina 3,4,5-substituidos.